EP2968246A4 - OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE - Google Patents

OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE

Info

Publication number
EP2968246A4
EP2968246A4 EP13878433.5A EP13878433A EP2968246A4 EP 2968246 A4 EP2968246 A4 EP 2968246A4 EP 13878433 A EP13878433 A EP 13878433A EP 2968246 A4 EP2968246 A4 EP 2968246A4
Authority
EP
European Patent Office
Prior art keywords
omega
methods
pentanoic acid
acid compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13878433.5A
Other languages
German (de)
French (fr)
Other versions
EP2968246A1 (en
Inventor
Abdel Aziz Fawzy
George Bobotas
Roelof Rongen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Publication of EP2968246A1 publication Critical patent/EP2968246A1/en
Publication of EP2968246A4 publication Critical patent/EP2968246A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Edible Oils And Fats (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP13878433.5A 2013-03-13 2013-12-17 OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE Withdrawn EP2968246A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780948P 2013-03-13 2013-03-13
PCT/US2013/075661 WO2014143272A1 (en) 2013-03-13 2013-12-17 Omega-3 pentaenoic acid compositions and methods of use

Publications (2)

Publication Number Publication Date
EP2968246A1 EP2968246A1 (en) 2016-01-20
EP2968246A4 true EP2968246A4 (en) 2016-08-03

Family

ID=51537458

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13878433.5A Withdrawn EP2968246A4 (en) 2013-03-13 2013-12-17 OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE
EP14779339.2A Withdrawn EP2986148A2 (en) 2013-03-13 2014-03-12 Compositions comprising docosapentaenoic acid and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14779339.2A Withdrawn EP2986148A2 (en) 2013-03-13 2014-03-12 Compositions comprising docosapentaenoic acid and methods of use

Country Status (4)

Country Link
EP (2) EP2968246A4 (en)
JP (2) JP2016518315A (en)
CA (2) CA2905671A1 (en)
WO (4) WO2014143272A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6750831B2 (en) * 2014-12-15 2020-09-02 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． Treatment of non-alcoholic fatty liver disease
CN106692973A (en) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 A kind of composition and its use, pharmaceutical preparation
CA3023648C (en) * 2016-05-10 2023-11-28 Shenzhen Hightide Biopharmaceutical, Ltd. Pharmaceutical composition of berberine with epa and dha
JP2020508285A (en) * 2017-02-09 2020-03-19 エス．エル．アー． ファーマ アーゲー High-purity eicosapentaenoic acid as a free fatty acid reduces stool calprotectin levels in patients with ulcerative colitis and prevents clinical recurrence
CN107006809B (en) * 2017-04-11 2020-06-09 江南大学 Vinegar onion product with blood fat reducing effect and preparation method thereof
JP7099821B2 (en) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 PCSK9 inhibitor and food composition for improving cholesterol metabolism
AU2020370081A1 (en) * 2019-10-25 2022-06-02 Nuseed Pty Ltd. Enriched polyunsaturated fatty acid compositions
CN118993893B (en) * 2024-08-07 2025-06-17 蓝平 EPA derivative and its preparation method and use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622467A1 (en) * 2003-05-05 2006-02-08 Denofa AS Fish oils with an altered fatty acid profile, method of producing same and their use
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
CA2588166A1 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2007058523A1 (en) * 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
RU2505292C2 (en) * 2009-02-10 2014-01-27 Амарин Фармасьютикалз Айрлэнд Лимитед Methods of treating hypertriglyceridemia
CN102421422A (en) * 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 Compositions comprising fatty acid oil mixtures and surfactants, methods and uses thereof
CN107233337A (en) * 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 Pharmaceutical composition containing EPA and cardiovascular agents and use its method
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
EP3335713B1 (en) * 2009-10-29 2022-08-31 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
WO2013033618A1 (en) * 2011-09-02 2013-03-07 Arctic Nutrition As Lipid compositions with high dha content

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014143272A1 *

Also Published As

Publication number Publication date
JP2016512544A (en) 2016-04-28
WO2014143275A1 (en) 2014-09-18
CA2905671A1 (en) 2014-09-18
CA2905795A1 (en) 2014-10-09
WO2014143272A1 (en) 2014-09-18
WO2014158256A1 (en) 2014-10-02
EP2968246A1 (en) 2016-01-20
EP2986148A2 (en) 2016-02-24
JP2016518315A (en) 2016-06-23
WO2014165190A3 (en) 2015-01-29
WO2014165190A2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
FR26C1005I1 (en) COMPOSITIONS AND METHODS OF MODULATING THE EXPRESSION OF APOLIPOPROTEIN C-III
FR26C1011I1 (en) THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
EP2861227A4 (en) OMEGA-3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE
MA41999A (en) OBETICHOLIC ACID COMPOSITIONS AND METHODS OF USE
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
IL249821A0 (en) Preparations of omega 3 fatty acid esters
MA43387A (en) ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
MA42925A (en) ANTI-TIGIT ANTIBODIES AND METHODS OF USE
EP2841443A4 (en) SERPINC1 TARGET RNAI COMPOSITIONS AND METHODS OF USE
EP2915557A4 (en) MICRO-NEEDLE OF RETINOIC ACID
EP3735963C0 (en) SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACID
EP2961382A4 (en) TOPICAL COMPOSITIONS AND METHODS OF USE
EP2834322A4 (en) BIOCHARBON COMPOSITIONS AND METHODS OF USE
EP2892562A4 (en) ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE
EP2983661A4 (en) FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES
EP2968280A4 (en) SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE
MA43385A (en) NEW ANTI-CLAUDINE ANTIBODIES AND METHODS OF USE
EP2996694A4 (en) CENICRIVIROC COMPOSITIONS AND METHODS OF MAKING AND USING THEM
MA43282A (en) NEW ANTI-EMR2 ANTIBODIES AND RELATED METHODS OF USE
EP3113613A4 (en) LIPOIC ACID CHOLINE ESTER COMPOSITIONS AND METHODS OF USING SAME
FR3009208B1 (en) HEAD OF DISTRIBUTION AND APPLICATION
EP2897639A4 (en) IMPROVED VACCINE COMPOSITIONS AND METHODS OF USE
MA42118A (en) BENZAMIDES SUBSTITUTED AND THEIR METHODS OF USE
EP2971042A4 (en) NEUTRALIZING ANTIBODIES FLAVIVIRUS AND METHODS OF USE
EP2988764A4 (en) ANTI-DANDRUFF COMPOSITIONS AND METHODS OF USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160704

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/232 20060101ALI20160628BHEP

Ipc: A61K 31/202 20060101AFI20160628BHEP

Ipc: A61K 9/48 20060101ALI20160628BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170201